Home > Rheumatology > ACR 2020 > COVID-19 – What Rheumatologists Need to Know > Poor disease control: a risk factor for severe COVID-19

Poor disease control: a risk factor for severe COVID-19

Presented By
Prof. Rebecca Grainger, University of Otago, New Zealand
Conference
ACR 2020
Trial
COVID-19 Global Rheumatology Alliance Registry
Data from the COVID-19 Global Rheumatology Alliance Registry showed that high disease activity is a risk factor for poor outcomes from COVID-19. “Our registry is a global initiative where cases from Europe are entered by the EULAR and cases in the USA by the ACR,” Prof. Rebecca Grainger (University of Otago, New Zealand) explained [1]. Three analyses were presented during the meeting. The risk of hospitalisation was assessed after the first month of the registry in the European and US cohort, risk factors for death in July in the American cohort, and outcome disparities in the global cohort that included data until August. In the first analysis, 600 cases were included: 277 were hospitalised (46%), 55 died (9%). Most patients suffered from rheumatoid arthritis (RA; 38%) and comorbidities were common. Patients aged >65 years had a 2.55-fold increased risk of hospitalisation. The hospitalisation risk of patients that were treated with a prednisone...


Please login to read the full text of the article.


If you have no account yet, please register now.





Posted on